|
DNAJC16 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.8481001131745E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.93639999590545E-08 |
| Normal-vs-Stage2 |
1.100410E-03 |
| Normal-vs-Stage3 |
4.24200008453113E-10 |
| Normal-vs-Stage4 |
3.91869980909121E-10 |
| Stage1-vs-Stage2 |
3.914600E-01 |
| Stage1-vs-Stage3 |
4.571600E-02 |
| Stage1-vs-Stage4 |
2.196500E-03 |
| Stage2-vs-Stage3 |
3.442100E-02 |
| Stage2-vs-Stage4 |
6.403300E-03 |
| Stage3-vs-Stage4 |
2.972600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.74810191164465E-11 |
| Normal-vs-AfricanAmerican |
1.578500E-03 |
| Normal-vs-Asian |
1.57711999999588E-05 |
| Caucasian-vs-AfricanAmerican |
4.338600E-01 |
| Caucasian-vs-Asian |
6.947200E-01 |
| AfricanAmerican-vs-Asian |
6.486800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.18360000081574E-08 |
| Normal-vs-Female |
3.44830053400358E-10 |
| Male-vs-Female |
5.848200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.10400000036459E-07 |
| Normal-vs-Age(41-60Yrs) |
3.8898000376264E-09 |
| Normal-vs-Age(61-80Yrs) |
5.01609997982655E-09 |
| Normal-vs-Age(81-100Yrs) |
1.296720E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.929230E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.808400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.859850E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.537400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.822000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.563000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.100200E-03 |
| Classical-VS-Follicular |
3.794000E-01 |
| Classical-VS-Other |
6.620200E-01 |
| Classical-VS-Normal |
1.74430003774262E-09 |
| Tall-VS-Follicular |
1.201050E-03 |
| Tall-VS-Other |
2.898600E-01 |
| Tall-VS-Normal |
1.07580000463514E-09 |
| Follicular-VS-Other |
5.205200E-01 |
| Follicular-VS-Normal |
1.355960E-04 |
| Other-VS-Normal |
1.717740E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.28249999906427E-08 |
| Normal-vs-N1 |
4.9653999800725E-09 |
| N0-vs-N1 |
4.922100E-02 |
|
|
